Treat refractory GERD with Metozolv ODT
When preventive measures and other medications fail to treat your GERD symptoms, Metozolv ODT may provide symptom relief and refractory GERD treatment. Metozolv ODT is the first available orally disintegrating metoclopramide tablet.1-3 This feature makes it convenient to take your medicine as prescribed because you can take it anywhere, on the go, without liquid.
Metozolv ODT treats refractory GERD1 by increasing pressure on the lower esophageal sphincter—the valve between the esophagus and the stomach that helps prevent acidic contents from entering the esophagus. It also helps move food out of the stomach by relaxing the pyloric valve, thereby helping to reduce symptoms.
Metozolv ODT provides convenient refractory GERD treatment
Metozolv ODT is an orally disintegrating tablet that treats refractory GERD.1 It rapidly* melts on the tongue and doesn’t require additional liquid that may add to gastric volume. That means you can take it when liquid is not available or if you have difficulty swallowing.
To find out if Metozolv ODT is right for you, talk to your healthcare professional.
Common symptoms of refractory GERD
See a list of questions you can ask your healthcare professional about Metozolv ODT
Learn more about Metozolv ODT
*Metozolv ODT disintegrates on the tongue in a median of 53.5 seconds (mean ± standard deviation, 76.8 ± 110.6 seconds).1
References: 1. METOZOLV ODT [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2009.
2. Overview. US Food and Drug Administration. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=REGLAN. Accessed May 6, 2009.
3. Overview. US Food and Drug Administration. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=METOCLOPRAMIDE%20HYDROCHLORIDE. Accessed May 6, 2009.
IMPORTANT SAFETY INFORMATION
Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive
dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive
dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh
the risk of developing tardive dyskinesia.
METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD)
who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric
stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage,
or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal
reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms;
neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience
withdrawal symptoms after stopping the use of METOZOLV ODT.
In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.
Please see accompanying full Prescribing Information
for Metozolv ODT, including BOXED WARNING.